Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
– Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent… Read More
Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma
– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support… Read More
Atsena gets Bain’s support in $150M Series C to thwart blindness with gene therapy
There’s still money to be raised by gene therapy startups with good clinical data. On Wednesday, North Carolina biotech Atsena Therapeutics said it had raised… Read More
Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow
Atsena Therapeutics’ $150 million fundraise is a light of hope for the gene therapy field, which has suffered enormously in recent months. Atsena Therapeutics has… Read More
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Strong investor syndicate backs clinical-stage Hepatitis B program while advancing pioneering gene-tuning platform DURHAM, N.C. & SEATTLE–(BUSINESS WIRE)–Leading epigenome editing company Tune Therapeutics… Read More
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Study AER-01-002 is using a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) patients AER-01-002 is well powered… Read More
HistoSonics Announces Oversubscribed $102 Million Series D Financing to Scale Launch of Non-Invasive Histotripsy Platform
Funding to Advance New Histotripsy Applications and Launch Innovative BOOMBOX Master Study HistoSonics Edison® Histotripsy System (Photo: Business Wire)… Read More
Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes
Oversubscribed financing led by strategic investor, with participation from new and existing investors MINNEAPOLIS, June 25, 2024 /PRNewswire/ — Endogenex, a clinical-stage medical device company dedicated to… Read More
A top Research Triangle based venture capital investor shares an overview of the life sciences ecosystem in North Carolina.
Hatteras Venture Partners’ Clay Thorp describes the growth of North Carolina’s biotech industry during his firm’s 20+ years of experience, and describes what the region… Read More
The Robert A. Ingram Fellowship for Excellence in Board Governance
The NACD Research Triangle Chapter, together with RTI International, is delighted to announce a fellowship award in honor of Robert A. Ingram, acknowledging his exceptional… Read More